KRAS变异亚型与手术切除肝内胆管癌生存及复发的关联
该单中心队列研究纳入2009年1月至2016年12月在中国一家医院接受根治性切除的1024例肝内胆管癌患者,采用全外显子组测序、靶向测序和Sanger测序鉴定KRAS变异。127例(12.4%)检出14种KRAS体细胞变异亚型,G12D最常见(55/127,43.3%)。多因素分析显示G12 KRAS变异(而非非G12变异)与更差的总生存(HR 1.69,95%CI 1.31-2.18,P<.001)和无病生存(HR 1.47,95%CI 1.16-1.88,P=.002)独立相关;G12V亚型预后最差(OS HR 3.05,95%CI 1.94-4.79,P<.001;DFS HR 1.79,95%CI 1.13-2.85,P=.01)。
要点
- 1024例手术切除ICC中127例(12.4%)检出KRAS变异,G12D最常见(43.3%)。
- G12 KRAS变异独立关联更差OS(HR 1.69)和DFS(HR 1.47),非G12变异无此关联。
- G12V亚型预后最差,OS HR 3.05、DFS HR 1.79。
核心结论
- G12 KRAS变异(而非非G12变异)与手术切除肝内胆管癌更差生存和更高复发风险相关,G12V亚型结局最差。
研究设计与样本
- 单中心队列研究,纳入2009年1月至2016年12月在中国一家医院接受根治性切除的1024例肝内胆管癌患者,采用全外显子组测序、靶向测序和Sanger测序鉴定KRAS变异,数据分析时间为2020年4月至2021年1月。
主要发现
- 127例(12.4%)检出14种KRAS体细胞变异亚型,G12D占55/127(43.3%),G12V占25/127(19.7%),G12C占9/127(7.1%),G13D占8/127(6.3%)。
- KRAS变异患者较野生型更常见CA19-9升高(92/127[72.4%] vs 546/897[60.9%],P=.01)和γ-谷氨酰转移酶升高(72/127[56.7%] vs 420/897[46.8%],P=.04)。
- 多因素分析显示G12 KRAS变异独立关联更差OS(HR 1.69,95%CI 1.31-2.18,P<.001)和DFS(HR 1.47,95%CI 1.16-1.88,P=.002),非G12变异无此独立关联。
- G12V亚型预后最差:OS HR 3.05(95%CI 1.94-4.79,P<.001),DFS HR 1.79(95%CI 1.13-2.85,P=.01)。
关键数值与推荐
- KRAS变异亚型分布:G12D 43.3%(55/127)、G12V 19.7%(25/127)、G12C 7.1%(9/127)、G13D 6.3%(8/127)。
- G12 KRAS变异 vs 野生型:OS HR 1.69(95%CI 1.31-2.18,P<.001),DFS HR 1.47(95%CI 1.16-1.88,P=.002)。
- G12V亚型:OS HR 3.05(95%CI 1.94-4.79,P<.001),DFS HR 1.79(95%CI 1.13-2.85,P=.01)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: KRAS variants are associated with tumor progression; however, the prevalence of KRAS variant subtypes and their association with survival and recurrence in patients with intrahepatic cholangiocarcinoma (ICC) after curative resection are largely unknown. OBJECTIVE: To explore the prognostic association of KRAS variant subtypes with survival and recurrence in patients with ICC. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, patients who underwent curative resection for ICC from January 2009 through December 2016 at a single hospital in China were recruited, and whole-exome sequencing, targeted sequencing, and Sanger sequencing were performed to identify KRAS variants. Kaplan-Meier and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS). Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Data were analyzed from April 2020 to January 2021. INTERVENTIONS: Hepatectomy in patients with ICC. MAIN OUTCOMES AND MEASURES: The association of KRAS variant subtypes with OS and DFS. RESULTS: Of 1024 included patients with ICC, 621 (60.6%) were male, and the mean (SD) age was 59.2 (10.2) years. A total of 14 different subtypes of KRAS somatic variants affecting 127 patients (12.4%) were identified. G12D was the most frequent allele in this cohort, accounting for 55 of 127 identified KRAS variants (43.3%), followed by G12V (25 [19.7%]), G12C (9 [7.1%]), and G13D (8 [6.3%]). Compared with patients with wild-type KRAS, patients with variant KRAS were more likely to have high levels of carbohydrate antigen 19-9 (92 of 127 [72.4%] vs 546 of 897 [60.9%]; P = .01) and γ-glutamyltransferase (72 of 127 [56.7%] vs 420 of 897 [46.8%]; P = .04). Multivariable analysis revealed that G12 KRAS variants but not non-G12 KRAS variants were independently associated with worse OS (hazard ratio [HR], 1.69; 95% CI, 1.31-2.18; P < .001) and DFS (HR, 1.47; 95% CI, 1.16-1.88; P = .002). Among the patients with G12 KRAS variants, the G12V KRAS variant was the strongest prognostic determinant for the worst OS (HR, 3.05; 95% CI, 1.94-4.79; P < .001) and DFS (HR, 1.79; 95% CI, 1.13-2.85; P = .01). CONCLUSIONS AND RELEVANCE: In this cohort study, the distribution of KRAS variant subtypes was characterized in a large cohort of patients with ICC from China. The presence of G12 KRAS variants but not non-G12 KRAS variants was associated with worse survival and increased risk of recurrence. Patients with the G12V variant exhibited the worst outcomes in the whole cohort.
引用
- Zhou SL, Xin HY, Sun RQ, et al. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surg. 2022. PMID: 34730772. doi:10.1001/jamasurg.2021.5679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。